Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in
participants with R/R AML or participants with R/R intermediate- to high-risk MDS.